Quidel Says FDA Grants CLIA Waiver For QuickVue RSV Test - Quick Facts

(RTTNews) - Quidel Corp. (QDEL | news | PowerRating | PR Charts ) on Friday said the U.S. Food and Drug Administration granted CLIA waiver for the QuickVue RSV test for the qualitative detection of respiratory syncytial virus or RSV.

RSV is the leading cause of pneumonia and bronchiolitis among children two years of age and younger. It is a common virus and the symptoms often resemble the common cold. The QuickVue RSV test is intended for use as an aid in the diagnosis of acute RSV viral infections for symptomatic pediatric patients.

The QuickVue RSV test is simple and accurate, with high sensitivity and specificity. The waiver makes the QuickVue RSV test more widely available for use, especially in physician offices and clinics where waived tests are used most frequently.

For comments and feedback: contact editorial@rttnews.com Copyright(c) 2008 RealTimeTraders.com, Inc. All Rights Reserved

More News:   Market Updates | Stock Alerts | All Trading News | Stock Index